MIAMI - s4story -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP), a clinical-stage biopharmaceutical company pioneering NMDA-based therapeutics for central nervous system disorders, is emerging as a potential leader in the next generation of depression and suicidality treatments. With its innovative ONE-D (One Day Depression) protocol now launched in Florida and a $40 price target set by H.C. Wainwright, NRXP appears positioned for transformational growth in a rapidly expanding $3.35 billion global market.

A Major Step Forward: ONE-D Depression Treatment Launches in Florida

NRx Pharmaceuticals has initiated the first-in-Florida rollout of the ONE-D (One Day) Depression Treatment, in partnership with Ampa Health. The innovative protocol has shown breakthrough potential in achieving remission from treatment-resistant depression within a single day—an unprecedented leap forward for millions suffering from chronic depression.

Unlike traditional transcranial magnetic stimulation (TMS) therapies requiring up to 90 sessions over three months, the ONE-D approach combines a single-day TMS treatment with physician-prescribed compounds, including D-cycloserine, an active component of NRx's investigational NRX-101, and lisdexamfetamine. Early clinical data show an 87% response rate and 72% remission rate in nonrandomized studies.

The Ampa device is now available across NRXP HOPE Clinics in Sarasota, Naples, and Fort Myers, Florida—with six total locations expected by the end of 2025. This initiative marks one of the first national deployments of the Ampa ONE-D protocol.

More on S For Story

• Your Enduring Purpose LLC Launches the Camp Daily Wins Journal to Strengthen Daily Resilience
• 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree
• From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
• Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
• Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation

Breakthrough Therapeutic Portfolio: NRX-101 and KETAFREE™

At the center of NRXP's drug pipeline is NRX-101, an FDA-designated Breakthrough Therapy targeting suicidal, treatment-resistant bipolar depression and chronic pain. The drug represents a potentially lifesaving option for the more than 13 million Americans who seriously consider suicide each year, according to the CDC.

NRXP is also advancing KETAFREE™, a preservative-free IV ketamine formulation, through a refiled Abbreviated New Drug Application (ANDA) with the FDA. This comes as the ketamine market—currently valued at $750 million—is projected to reach $3.35 billion globally by 2034.

Importantly, the FDA has granted approval of NRXP's Suitability Petition for its proposed strength of preservative-free ketamine, clearing the path for potential market entry amid ongoing national shortages of sterile ketamine formulations.

Strategic Expansion Through Dura Medical Acquisition

NRXP recently completed its acquisition of Dura Medical, a revenue-generating and EBITDA-positive network of precision psychiatry clinics along Florida's West Coast. The addition of Dura, alongside pending acquisitions such as Neurospa TMS and Cohen & Associates, positions NRXP to deliver an integrated continuum of mental health care spanning TMS, ketamine therapy, and advanced pharmacologic treatments for PTSD, depression, and chronic pain.

Robust Financial and Partnership Outlook

The company's growth strategy is supported by a $7.8 million debt financing deal with Universal Capital, LLC, aimed at expanding NRXP's HOPE Clinic network. In parallel, NRXP has accepted non-binding potential licensing terms for NRX-100, with the agreement representing over $300 million in milestone payments and tiered double-digit royalties—a major value inflection opportunity for investors.

More on S For Story

• Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport
• Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle
• T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
• Record Revenues, Debt-Free Momentum & Shareholder Dividend Ignite Investor Attention Ahead of 2026–2027 Growth Targets: IQSTEL (N A S D A Q: IQST)
• New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life

Moreover, NRXP's partnership with Alvogen Pharmaceuticals supports the ongoing development and commercial readiness of NRX-101, further validating the company's clinical and commercial trajectory.

Analyst Confidence: H.C. Wainwright Issues "Buy" Rating and $40 Price Target

A recent analyst report from H.C. Wainwright & Co. titled "A Paradigm Shift in the Treatment of Depression with Suicidality" initiated coverage on NRx Pharmaceuticals with a Buy rating and a $34 price target. The report underscores NRXP's leadership in transforming how depression and suicidality are treated, leveraging FDA Fast Track and Breakthrough Therapy designations to accelerate commercialization.

"We view NRXP's approach as a paradigm shift in the treatment of depression with suicidality," wrote H.C. Wainwright analysts. "With novel drug candidates, a rapidly expanding clinic network, and strategic licensing opportunities, NRXP is uniquely positioned to capture substantial market share."

About NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing breakthrough therapeutics based on its NMDA receptor modulation platform for the treatment of central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD.

Through its partnerships, innovative clinical pipeline, and integrated treatment model, NRXP is setting new standards in precision psychiatry and interventional mental health care.

For More Information:
Company: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Website: www.nrxpharma.com
Phone: (484) 254-6134

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website